Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 63, Issue 4, 2002, Pages 308-315

  Detke, Michael J ^a   Lu, Yili ^a   Goldstein, David J ^a   Hayes, John R ^a   Demitrack, Mark A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DESIPRAMINE; DULOXETINE; FLUOXETINE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE; ZOLPIDEM TARTRATE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SYMPTOMATOLOGY; VISUAL ANALOG SCALE; XEROSTOMIA;

EID: 0036232639     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0407     Document Type: Article

References (40)

1. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
2. Citalopram, clinical effect profile in comparison with clomipramine: A controlled multicenter study
3. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study
4. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression
5. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors
6. Duloxetine: Clinical evidence of serotonergic and noradrenergic reuptake blockade
7. Evidence of the dual mechanisms of action of venlafaxine
8. Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry
9. Descending noradrenergic influences on pain
10. Multiplicity and plasticity of descending modulation of nociception: Implications for persistent pain
11. Serotonin and nociception
12. Neuroanatomy of the pain system and the pathways that modulate pain
13. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: A quantitative systematic review
14. Antidepressants as analgesics: A review of randomized controlled trials
15. The use of antidepressants in the treatment of chronic pain: A review of the current evidence
16. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action
17. Effects of duloxetine, a potent and selective 5HT/NE reuptake inhibitor, in rat models of persistent and neuropathic pain
18. Clinical predictors of mental disorders among medical outpatients
19. The relationship of presenting physical complaints to depressive symptoms in primary care patients
20. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial
21. Duloxetine (LY-248686): An inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate
22. Drug distribution between blood and brain as a determinant of antipsychotic drug effects
23. Persistence of haloperidol in human brain tissue
24. Administration of antidepressants single versus split dosing: A meta-analysis
25. A systematic review of the associations between dose regimens and medication compliance
26. The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
27. A rating scale for depression
28. Development of a rating scale for primary depressive illness
29. The visual analog scale in the immediate postoperative period: Intrasubject variability and correlation with a numeric scale
30. The QLDS: A scale for the measurement of quality of life in depression
31. Measuring onset of antidepressant action in clinical trials: An overview of definitions and methodology
32. Accounting for dropout bias using mixed-effects models
33. Type I error rates from mixed-effects model repeated measures compared with fixed-effects ANOVA with missing values imputed via LOCE
34. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates
35. Newer antidepressants: A comparison of tolerability in general practice